Papers

11

Total Citations

1,645

H-Index

8

About

Eila C. Skinner is a leading urologic oncologist whose research has fundamentally shaped the surgical management of bladder cancer, particularly through rigorous evaluation of robotic versus open surgical techniques. She is best known as the lead investigator of the landmark RAZOR trial, the first multicenter, randomized phase 3 study to demonstrate that robot-assisted radical cystectomy is non-inferior to open surgery for progression-free survival, a finding published in *The Lancet* (760 citations). Her work has provided the highest level of evidence supporting the oncologic safety of robotic cystectomy, directly influencing surgical practice worldwide. Beyond the RAZOR trial, Dr. Skinner has authored seminal systematic reviews (444 citations) and co-chaired the Pasadena Consensus Panel, establishing best practices for robotic cystectomy and urinary reconstruction. She has also advanced surgical training through the development of the CASE assessment tool for robotic cystectomy. Her cumulative work, including extended follow-up analyses from RAZOR and studies on lymphadenectomy and perioperative outcomes, has been cited over 1,600 times, cementing her role as a pivotal figure in evidence-based urologic oncology.

Research Focus

Key Achievements

8
H-Index
11
Papers
1,645
Total Citations
150
Avg Citations/Paper
🏆 Most Cited Paper
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
760 citations · 2018
📈 Most Prolific Year: 2015 (3 Papers)
🤝 Key Collaborators: 99
🏛 Institutions: Stanford University, University of Southern California, Keck Hospital of USC

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
    Continent cutaneous diversion
    17 citations · 2015
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago